|Day Low/High||1.24 / 1.51|
|52 Wk Low/High||1.52 / 13.11|
Spherix Incorporated Acquires 6,800,000 shares of Hoth Therapeutics
Hoth's BioLexa platform uses its proprietary technology to treat eczema without the use of traditional topical steroids.
Spherix and Equitable IP Acquire Rights to Monetize 112 New Patents
Spherix Partners with Numedeon and VWIP Inc., leading E-Learning Companies to explore IP Monetization
Trade-Ideas LLC identified Spherix (SPEX) as a weak on high relative volume candidate
Shares of Spherix (SPEX) are rising Tuesday morning after the company announced a second licensing deal with RPX (RPXC).
TheStreet highlights 3 stocks that pushed the Health Services industry
TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,300 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: BSFT, GSL, ODC, SSP, TUMI Downgrades: AETI, CHMG, INS, KOG, L, LPTH, SVT, VIVO, WRES Initiations: CBFV, PBPB, SPEX Read on to get TheStreet Quant Ratings' detailed report:
Keep these stocks trading for less than $10 a share on your breakout trading radar.
Spherix (SPEX) is up after it announced it has commenced patent litigation against Huawei Technologies, the Chinese networking and telecom company,
Spherix (SPEX) rose Tuesday after the intellectual property development company announced it had supported its balance sheet with $20 million in equity financing.
Spherix (SPEX) plunged Thursday after the intellectual property development company announced a registered direct offering of preferred stock.
Spherix (SPEX) continued to soar on Wednesday after shares of the intellectual property development company exploded on Tuesday.
Speculative money has returned to the markets with a vengeance in the small-cap arena.
Spherix (SPEX) soared Tuesday after the U.S. Senate and Senate Judiciary Committee Chairman Patrick Leahy removed a patent reform bill from the committee's calendar due to a lack of bipartisan support.
Consider buying this oversold stock as it gears up for a big move higher.
These under-$10 stocks are within range of triggering breakout trades.
Shares of Spherix (SPEX) were down 23% to $3.45 in trading Thursday.